Lifemd, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lifemd, Inc. has an operating margin of -8.8%, meaning the company retains $-9 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -9.5% the prior year.
Lifemd, Inc.'s revenue surged 36.9% year-over-year to $208.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Lifemd, Inc.'s current ratio of 0.78 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 11/100, which could limit financial flexibility.
Lifemd, Inc. has a free cash flow margin of 7.7%, earning a moderate score of 38/100. The company generates positive cash flow after capital investments, but with room for improvement.
Lifemd, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Lifemd, Inc. generates $-0.82 in operating cash flow ($17.5M OCF vs -$21.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Lifemd, Inc. earns $-8.4 in operating income for every $1 of interest expense (-$18.3M vs $2.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Lifemd, Inc. (LFMDP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Lifemd, Inc. generated $208.8M in revenue in fiscal year 2024. This represents an increase of 36.9% from the prior year.
Lifemd, Inc.'s EBITDA was -$16.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.2% from the prior year.
Lifemd, Inc. generated $16.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 86.0% from the prior year.
Lifemd, Inc. reported -$21.4M in net income in fiscal year 2024. This represents a decrease of 3.9% from the prior year.
Lifemd, Inc. earned $-0.60 per diluted share (EPS) in fiscal year 2024. This represents an increase of 14.3% from the prior year.
Lifemd, Inc. held $35.0M in cash against $0 in long-term debt as of fiscal year 2024.
Lifemd, Inc. had 42M shares outstanding in fiscal year 2024. This represents an increase of 10.3% from the prior year.
Lifemd, Inc.'s gross margin was 88.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the prior year.
Lifemd, Inc.'s operating margin was -8.8% in fiscal year 2024, reflecting core business profitability. This is up 0.8 percentage points from the prior year.
Lifemd, Inc.'s net profit margin was -10.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 3.3 percentage points from the prior year.
Lifemd, Inc. invested $1.5M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 631.5% from the prior year.
LFMDP Income Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $60.2M-1.0% | $60.8M+19.9% | $50.7M+14.8% | $44.1M-1.6% | $44.9M+16.2% | $38.6M+7.4% | $35.9M+8.5% | $33.1M |
| Cost of Revenue | $7.4M-21.4% | $9.4M+87.7% | $5.0M+9.2% | $4.6M-14.1% | $5.4M+12.0% | $4.8M+5.1% | $4.5M+7.9% | $4.2M |
| Gross Profit | $52.8M+2.8% | $51.3M+12.5% | $45.6M+15.4% | $39.5M+0.1% | $39.5M+16.8% | $33.8M+7.8% | $31.4M+8.6% | $28.9M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $16.6M-13.8% | $19.2M+3.9% | $18.5M+21.0% | $15.3M-1.7% | $15.6M+16.2% | $13.4M+10.6% | $12.1M+14.3% | $10.6M |
| Operating Income | -$2.0M-9.2% | -$1.8M+71.4% | -$6.3M-2.2% | -$6.2M-184.2% | -$2.2M+52.5% | -$4.6M+6.7% | -$4.9M-71.6% | -$2.9M |
| Interest Expense | $262K-57.3% | $614K+15.5% | $531K+11.3% | $478K-23.3% | $623K-12.8% | $714K-28.3% | $996K+276.5% | $264K |
| Income Tax | $169K-27.3% | $233K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.8M-22.5% | -$3.1M+54.8% | -$6.9M-1.6% | -$6.8M-81.4% | -$3.7M+39.0% | -$6.1M+9.1% | -$6.7M-68.0% | -$4.0M |
| EPS (Diluted) | $-0.10-11.1% | $-0.09+52.6% | $-0.190.0% | $-0.19-58.3% | $-0.12+40.0% | $-0.20+13.0% | $-0.23-53.3% | $-0.15 |
LFMDP Balance Sheet
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $66.0M-13.3% | $76.1M+19.2% | $63.8M+3.8% | $61.5M+5.1% | $58.5M+43.7% | $40.7M+14.8% | $35.4M+4.7% | $33.9M |
| Current Assets | $41.1M-21.5% | $52.4M+16.2% | $45.1M+1.5% | $44.4M+4.2% | $42.6M+71.2% | $24.9M+23.3% | $20.2M+5.3% | $19.2M |
| Cash & Equivalents | $23.8M-32.1% | $35.0M-2.0% | $35.7M+1.7% | $35.1M+5.9% | $33.1M+116.8% | $15.3M+28.4% | $11.9M+3.3% | $11.5M |
| Inventory | $3.4M+22.7% | $2.8M+35.7% | $2.1M-13.2% | $2.4M-14.0% | $2.8M-27.2% | $3.8M+2.5% | $3.7M+9.3% | $3.4M |
| Accounts Receivable | $9.2M-14.8% | $10.9M+91.5% | $5.7M+6.2% | $5.3M-14.8% | $6.3M+41.8% | $4.4M+20.4% | $3.7M+24.9% | $2.9M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $8.0M0.0% | $8.0M | $0 |
| Total Liabilities | $62.6M-25.1% | $83.7M+27.0% | $65.9M+9.5% | $60.2M+13.7% | $52.9M+2.2% | $51.8M+13.4% | $45.7M+10.7% | $41.2M |
| Current Liabilities | $56.7M-15.9% | $67.4M+30.5% | $51.6M+15.6% | $44.7M+28.4% | $34.8M+6.9% | $32.5M+3.2% | $31.5M+16.7% | $27.0M |
| Long-Term Debt | $15.9M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.3M+114.5% | -$9.1M-115.9% | -$4.2M-397.6% | -$845K-124.1% | $3.5M+127.7% | -$12.7M+20.9% | -$16.0M-33.4% | -$12.0M |
| Retained Earnings | -$247.8M-3.3% | -$239.9M-4.5% | -$229.5M-3.4% | -$221.8M-3.5% | -$214.3M-2.1% | -$209.8M-3.4% | -$202.9M-3.8% | -$195.3M |
LFMDP Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$147K-113.7% | $1.1M-76.4% | $4.5M-12.7% | $5.2M-9.0% | $5.7M+430.9% | $1.1M-76.8% | $4.6M+277.7% | -$2.6M |
| Capital Expenditures | $797K+253.7% | $225K-64.9% | $642K+265.7% | $176K+60.6% | $109K+261.3% | $30K-1.0% | $31K-9.2% | $34K |
| Free Cash Flow | -$944K-211.4% | $848K-78.2% | $3.9M-22.5% | $5.0M-10.3% | $5.6M+435.8% | $1.0M-77.3% | $4.6M+274.3% | -$2.6M |
| Investing Cash Flow | -$3.6M-32.1% | -$2.7M+13.1% | -$3.1M-43.0% | -$2.2M+1.2% | -$2.2M+7.8% | -$2.4M-4.4% | -$2.3M-27.0% | -$1.8M |
| Financing Cash Flow | -$8.7M-830.7% | -$935K-14.6% | -$815K+22.2% | -$1.0M-107.3% | $14.4M+205.0% | $4.7M+340.1% | -$2.0M-116.4% | $12.0M |
| Dividends Paid | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K |
| Share Buybacks | $270K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LFMDP Financial Ratios
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.7%+3.2pp | 84.5%-5.6pp | 90.1%+0.5pp | 89.6%+1.5pp | 88.1%+0.4pp | 87.6%+0.3pp | 87.4%+0.1pp | 87.3% |
| Operating Margin | -3.3%-0.3pp | -3.0%+9.5pp | -12.4%+1.5pp | -14.0%-9.1pp | -4.8%+7.0pp | -11.8%+1.8pp | -13.6%-5.0pp | -8.6% |
| Net Margin | -6.3%-1.2pp | -5.1%+8.5pp | -13.6%+1.8pp | -15.3%-7.0pp | -8.3%+7.5pp | -15.9%+2.9pp | -18.7%-6.6pp | -12.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -5.8%-1.7pp | -4.1%+6.7pp | -10.8%+0.2pp | -11.0%-4.6pp | -6.4%+8.7pp | -15.0%+3.9pp | -19.0%-7.2pp | -11.8% |
| Current Ratio | 0.73-0.1 | 0.78-0.1 | 0.87-0.1 | 0.99-0.2 | 1.22+0.5 | 0.77+0.1 | 0.64-0.1 | 0.71 |
| Debt-to-Equity | 47.64+56.8 | -9.21+6.5 | -15.66+55.5 | -71.17-86.3 | 15.10+19.2 | -4.09-1.2 | -2.85+0.6 | -3.43 |
| FCF Margin | -1.6%-3.0pp | 1.4%-6.3pp | 7.7%-3.7pp | 11.4%-1.1pp | 12.5%+9.8pp | 2.7%-10.1pp | 12.8%+20.8pp | -8.0% |
Note: Shareholder equity is negative (-$9.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Lifemd, Inc.'s annual revenue?
Lifemd, Inc. (LFMDP) reported $208.8M in total revenue for fiscal year 2024. This represents a 36.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lifemd, Inc.'s revenue growing?
Lifemd, Inc. (LFMDP) revenue grew by 36.9% year-over-year, from $152.5M to $208.8M in fiscal year 2024.
Is Lifemd, Inc. profitable?
No, Lifemd, Inc. (LFMDP) reported a net income of -$21.4M in fiscal year 2024, with a net profit margin of -10.3%.
What is Lifemd, Inc.'s earnings per share (EPS)?
Lifemd, Inc. (LFMDP) reported diluted earnings per share of $-0.60 for fiscal year 2024. This represents a 14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lifemd, Inc.'s EBITDA?
Lifemd, Inc. (LFMDP) had EBITDA of -$16.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lifemd, Inc.'s gross margin?
Lifemd, Inc. (LFMDP) had a gross margin of 88.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Lifemd, Inc.'s operating margin?
Lifemd, Inc. (LFMDP) had an operating margin of -8.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Lifemd, Inc.'s net profit margin?
Lifemd, Inc. (LFMDP) had a net profit margin of -10.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Lifemd, Inc.'s free cash flow?
Lifemd, Inc. (LFMDP) generated $16.0M in free cash flow during fiscal year 2024. This represents a 86.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lifemd, Inc.'s operating cash flow?
Lifemd, Inc. (LFMDP) generated $17.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Lifemd, Inc.'s total assets?
Lifemd, Inc. (LFMDP) had $76.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Lifemd, Inc.'s capital expenditures?
Lifemd, Inc. (LFMDP) invested $1.5M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How many shares does Lifemd, Inc. have outstanding?
Lifemd, Inc. (LFMDP) had 42M shares outstanding as of fiscal year 2024.
What is Lifemd, Inc.'s current ratio?
Lifemd, Inc. (LFMDP) had a current ratio of 0.78 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Lifemd, Inc.'s debt-to-equity ratio?
Lifemd, Inc. (LFMDP) had a debt-to-equity ratio of -9.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lifemd, Inc.'s return on assets (ROA)?
Lifemd, Inc. (LFMDP) had a return on assets of -28.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Lifemd, Inc.'s debt-to-equity ratio negative or unusual?
Lifemd, Inc. (LFMDP) has negative shareholder equity of -$9.1M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Lifemd, Inc.'s Piotroski F-Score?
Lifemd, Inc. (LFMDP) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lifemd, Inc.'s earnings high quality?
Lifemd, Inc. (LFMDP) has an earnings quality ratio of -0.82x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Lifemd, Inc. cover its interest payments?
Lifemd, Inc. (LFMDP) has an interest coverage ratio of -8.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Lifemd, Inc.?
Lifemd, Inc. (LFMDP) scores 37 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.